Michael Barber Purchases 15,175 Shares of DENTSPLY SIRONA (NASDAQ:XRAY) Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Michael Barber purchased 15,175 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the transaction, the director owned 55,943 shares of the company’s stock, valued at $552,716.84. This represents a 37.22% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

DENTSPLY SIRONA Price Performance

Shares of DENTSPLY SIRONA stock opened at $10.45 on Wednesday. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52. The company’s 50-day moving average price is $10.93 and its two-hundred day moving average price is $11.70. DENTSPLY SIRONA Inc. has a 52 week low of $9.40 and a 52 week high of $17.09. The stock has a market cap of $2.09 billion, a PE ratio of -3.32, a price-to-earnings-growth ratio of 1.21 and a beta of 0.89.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The business had revenue of $880.00 million during the quarter, compared to the consensus estimate of $841.80 million. During the same quarter last year, the firm posted $0.43 earnings per share. DENTSPLY SIRONA’s revenue was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, sell-side analysts anticipate that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current fiscal year.

Hedge Funds Weigh In On DENTSPLY SIRONA

A number of institutional investors have recently bought and sold shares of the stock. Southpoint Capital Advisors LP purchased a new position in DENTSPLY SIRONA during the 1st quarter valued at about $116,000,000. AQR Capital Management LLC grew its stake in DENTSPLY SIRONA by 109.8% during the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after acquiring an additional 6,970,086 shares in the last quarter. Armistice Capital LLC grew its stake in DENTSPLY SIRONA by 1,044.0% during the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after acquiring an additional 5,234,587 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in DENTSPLY SIRONA by 662.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after acquiring an additional 4,003,606 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after acquiring an additional 2,172,343 shares in the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Analysts Set New Price Targets

XRAY has been the topic of several research reports. Mizuho dropped their price target on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Citigroup initiated coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price target on the stock. Robert W. Baird lifted their price target on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Barclays dropped their price target on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research note on Thursday, June 4th. Finally, UBS Group dropped their price target on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, DENTSPLY SIRONA presently has an average rating of “Hold” and an average target price of $13.55.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.